Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery

Summary

A majority of the elderly patients undergo surgery for malignant tumors. For these patients, postoperative tumor recurrence and metastasis are main factors that worsen long-term outcomes. The investigators hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer surgery may help to maintain immune function and improve long-term outcomes, possibly by relieving stress and inflammatory response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.

Conditions

• Elderly
• Surgery
• Analgesia
• Dexmedetomidine
• Long-term Outcome

Interventions

DRUG

Dexmedetomidine supplemented morphine analgesia

Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.

DRUG

Morphine analgesia

Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.

Sponsors & Collaborators

• Affiliated Hospital of Hebei University

  collaborator OTHER

• Qingdao Municipal Hospital

  collaborator OTHER

• The Second Affiliated Hospital of Air Force Medical University

  collaborator UNKNOWN

• Peking University International Hospital

  collaborator OTHER

• Guizhou Provincial People's Hospital

  collaborator OTHER

• The Third Xiangya Hospital of Central South University

  collaborator OTHER

• Shanxi Provincial Cancer Hospital

  collaborator UNKNOWN

• Tianjin Hospital of ITCWM-Nankai Hospital

  collaborator UNKNOWN

• Chongqing University Fuling Hospital

  collaborator UNKNOWN

• The Third Central Hospital of Tianjin

  collaborator UNKNOWN

• Xiyuan Hospital of China Academy of Chinese Medical Sciences

  collaborator OTHER

• Peking University First Hospital

  lead OTHER

Principal Investigators

• Dong-Xin Wang, MD, PhD · Peking University First Hospital

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

65 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-01-06

Primary Completion

2024-12-11

Completion

2024-12-11

Countries

• China

Study Locations